Gastrointestinal Cancer Drugs Market by Therapy and Application - Global Industry Analysis & Forecast to 2027
Published On : October 2019 Pages : 160 Category: Pharma & Healthcare Report Code : HC106316
Gastrointestinal Cancer Drugs Market by Therapy (Immunotherapy, Adjuvant Chemotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy, and Radiation Therapy) Application (Oncology and Radiology) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The gastrointestinal cancer drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Gastrointestinal cancer is commonly a gathering of cancers influencing organs like stomach, nerve bladder, throat, bowels, rectum, butt, liver, and pancreas. The cancer growth can shape a mass or ulcer inside the stomach or it can spread diffusely all through the whole mass of the stomach. Stomach cancer growth is additionally called gastric cancer.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global gastrointestinal cancer drugs market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Eli Lilly
- CONMED Corporation.
- Stryker Corporation
- Roche
- Johnson & Johnson
- Novartis
- GlaxoSmithKline
- Boston Scientific Corporation
- Otsuka Holdings
- Merck
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Gastrointestinal Cancer Drugs Market , By Therapy, Estimates and Forecast, 2017-2027 ($Million)
o Immunotherapy
o Adjuvant Chemotherapy
o Targeted Therapy
o Chemotherapy
o Hormone Therapy
o Radiation Therapy
· Gastrointestinal Cancer Drugs Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Oncology
o Radiology
· Gastrointestinal Cancer Drugs Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Eli Lilly
o CONMED Corporation.
o Stryker Corporation
o Roche
o Johnson & Johnson
o Novartis
o GlaxoSmithKline
o Boston Scientific Corporation
o Otsuka Holdings
o Merck
· Gastrointestinal Cancer Drugs Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Gastrointestinal Cancer Drugs Market , By Country
o U.S. Gastrointestinal Cancer Drugs Market
o Canada Gastrointestinal Cancer Drugs Market
o Mexico Gastrointestinal Cancer Drugs Market
o Europe
§ Europe Gastrointestinal Cancer Drugs Market , By Country
· Germany Gastrointestinal Cancer Drugs Market
o UK Gastrointestinal Cancer Drugs Market
o France Gastrointestinal Cancer Drugs Market
o Russia Gastrointestinal Cancer Drugs Market
o Italy Gastrointestinal Cancer Drugs Market
o Rest of Europe Gastrointestinal Cancer Drugs Market
o Asia-Pacific
§ Asia-Pacific Gastrointestinal Cancer Drugs Market , By Country
o China Gastrointestinal Cancer Drugs Market
o Japan Gastrointestinal Cancer Drugs Market
o South Korea Gastrointestinal Cancer Drugs Market
o India Gastrointestinal Cancer Drugs Market
o Southeast Asia Gastrointestinal Cancer Drugs Market
o Rest of Asia-Pacific Gastrointestinal Cancer Drugs Market
o South America
§ South America Gastrointestinal Cancer Drugs Market
o Brazil Gastrointestinal Cancer Drugs Market
o Argentina Gastrointestinal Cancer Drugs Market
o Columbia Gastrointestinal Cancer Drugs Market
o Rest of South America Gastrointestinal Cancer Drugs Market
o Middle East and Africa
§ Middle East and Africa Gastrointestinal Cancer Drugs Market
o Saudi Arabia Gastrointestinal Cancer Drugs Market
o UAE Gastrointestinal Cancer Drugs Market
o Egypt Gastrointestinal Cancer Drugs Market
o Nigeria Gastrointestinal Cancer Drugs Market
o South Africa Gastrointestinal Cancer Drugs Market
o Rest of MEA Gastrointestinal Cancer Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Gastrointestinal Cancer Drugs Market, By Therapy
5.1. Introduction
5.2. Global Gastrointestinal Cancer Drugs Revenue and Market Share by Therapy (2017-2027)
5.2.1. Global Gastrointestinal Cancer Drugs Revenue and Revenue Share by Therapy (2017-2027)
5.3. Immunotherapy
5.3.1. Global Immunotherapy Revenue and Growth Rate (2017-2027)
5.4. Adjuvant Chemotherapy
5.4.1. Global Adjuvant Chemotherapy Revenue and Growth Rate (2017-2027)
5.5. Targeted Therapy
5.5.1. Global Targeted Therapy Revenue and Growth Rate (2017-2027)
5.6. Chemotherapy
5.6.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
5.7. Hormone Therapy
5.7.1. Global Hormone Therapy Revenue and Growth Rate (2017-2027)
5.8. Radiation Therapy
5.8.1. Global Radiation Therapy Revenue and Growth Rate (2017-2027)
6. Gastrointestinal Cancer Drugs Market, By Application
6.1. Introduction
6.2. Global Gastrointestinal Cancer Drugs Revenue and Market Share by Application (2017-2027)
6.2.1. Global Gastrointestinal Cancer Drugs Revenue and Revenue Share by Application (2017-2027)
6.3. Oncology
6.3.1. Global Oncology Revenue and Growth Rate (2017-2027)
6.4. Radiology
6.4.1. Global Radiology Revenue and Growth Rate (2017-2027)
7. Gastrointestinal Cancer Drugs Market, By Region
7.1. Introduction
7.2. Global Gastrointestinal Cancer Drugs Revenue and Market Share by Regions
7.2.1. Global Gastrointestinal Cancer Drugs Revenue by Regions (2017-2027)
7.3. North America Gastrointestinal Cancer Drugs by Countries
7.3.1. North America Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Gastrointestinal Cancer Drugs by Countries
7.4.1. Europe Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Gastrointestinal Cancer Drugs by Countries
7.5.1. Asia-Pacific Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Gastrointestinal Cancer Drugs by Countries
7.6.1. South America Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Gastrointestinal Cancer Drugs by Countries
7.7.1. Middle East and Africa Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Eli Lilly
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. CONMED Corporation.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Stryker Corporation
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Roche
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Johnson & Johnson
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Novartis
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. GlaxoSmithKline
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Boston Scientific Corporation
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Otsuka Holdings
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Merck
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.1. Global Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Gastrointestinal Cancer Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.1.1. United States Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2. Europe Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2.2. France Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2.3. UK Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3.1. China Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3.4. India Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.4. South America Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Gastrointestinal Cancer Drugs Market Forecast (2017-2027)
9.3. Gastrointestinal Cancer Drugs Market Forecast by Therapy (2017-2027)
9.3.1. Gastrointestinal Cancer Drugs Forecast by Therapy (2017-2027)
9.3.2. Gastrointestinal Cancer Drugs Market Share Forecast by Therapy (2017-2027)
9.4. Gastrointestinal Cancer Drugs Market Forecast by Application (2017-2027)
9.4.1. Gastrointestinal Cancer Drugs Forecast by Application (2017-2027)
9.4.2. Gastrointestinal Cancer Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Gastrointestinal Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Gastrointestinal Cancer Drugs Revenue and Revenue Share by Therapy (2017-2018)
Figure Global Immunotherapy Revenue and Growth Rate (2017-2018)
Figure Global Adjuvant Chemotherapy Revenue and Growth Rate (2017-2018)
Figure Global Targeted Therapy Revenue and Growth Rate (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Figure Global Hormone Therapy Revenue and Growth Rate (2017-2018)
Figure Global Radiation Therapy Revenue and Growth Rate (2017-2018)
Table Global Gastrointestinal Cancer Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Oncology Revenue and Growth Rate (2017-2018)
Figure Global Radiology Revenue and Growth Rate (2017-2018)
Table Global Gastrointestinal Cancer Drugs Revenue by Regions (2017-2018)
Figure North America Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure North America Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2018)
Figure North America Gastrointestinal Cancer Drugs by Countries (2017-2018)
Figure North America Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure United States Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Canada Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Mexico Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Europe Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Gastrointestinal Cancer Drugs by Countries (2017-2018)
Figure Europe Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Germany Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure France Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure UK Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Russia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Italy Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Rest of Europe Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Gastrointestinal Cancer Drugs by Countries (2017-2018)
Figure Asia-Pacific Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure China Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Japan Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Korea Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure India Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Southeast Asia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure South America Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2018)
Figure South America Gastrointestinal Cancer Drugs by Countries (2017-2018)
Figure South America Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Brazil Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Argentina Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Columbia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Rest of South America Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Gastrointestinal Cancer Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Gastrointestinal Cancer Drugs by Countries (2017-2018)
Figure Middle East and Africa Gastrointestinal Cancer Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Egypt Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Nigeria Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure South Africa Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Turkey Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Gastrointestinal Cancer Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Eli Lilly Gastrointestinal Cancer Drugs Financial Overview
Table CONMED Corporation. Gastrointestinal Cancer Drugs Financial Overview
Table Stryker Corporation Gastrointestinal Cancer Drugs Financial Overview
Table Roche Gastrointestinal Cancer Drugs Financial Overview
Table Johnson & Johnson Gastrointestinal Cancer Drugs Financial Overview
Table Novartis Gastrointestinal Cancer Drugs Financial Overview
Table GlaxoSmithKline Gastrointestinal Cancer Drugs Financial Overview
Table Boston Scientific Corporation Gastrointestinal Cancer Drugs Financial Overview
Table Otsuka Holdings Gastrointestinal Cancer Drugs Financial Overview
Table Merck Gastrointestinal Cancer Drugs Financial Overview
Figure Global Gastrointestinal Cancer Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Gastrointestinal Cancer Drugs Market Forecast by Regions (2018-2025)
Figure North America Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure United States Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Canada Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Mexico Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Europe Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Germany Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure France Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure UK Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Russia Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Italy Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Rest of Europe Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure China Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Japan Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Korea Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure India Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Southeast Asia Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure South America Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Brazil Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Argentina Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Columbia Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Rest of South America Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Egypt Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Nigeria Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure South Africa Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Turkey Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Gastrointestinal Cancer Drugs Market Forecast (2018-2025)
Figure Global Gastrointestinal Cancer Drugs Forecast by Therapy (2018-2025)
Figure Global Gastrointestinal Cancer Drugs Market Share Forecast by Therapy (2018-2025)
Figure Global Gastrointestinal Cancer Drugs Forecast by Therapy (2018-2025)
Figure Global Gastrointestinal Cancer Drugs Forecast by Application (2018-2025)
Figure Global Gastrointestinal Cancer Drugs Market Share Forecast by Application (2018-2025)
Figure Global Gastrointestinal Cancer Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|